Aetna Pancreaticoduodenectomy Coverage Update

Medically Necessary Indications

Aetna considers the following interventions medically necessary:

Medically necessary indications for pancreaticoduodenectomy: Pancreaticoduodenectomy is medically necessary for treatment of the following conditions: ampullary adenoma/carcinoma; cholangiocarcinoma; chronic pancreatitis; combined pancreatic/duodenal injury; duodenal neoplasm; intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia or invasive cancer; neuroendocrine tumors; pancreatic adenocarcinoma.

Documentation should support one of these indications and appropriate diagnosis coding.

Experimental and Investigational

Aetna considers the following experimental and investigational (not covered):

Experimental and investigational interventions: Pancreaticoduodenectomy for Zollinger-Ellison syndrome; pre-operative biliary drainage for prevention of post-operative complications; use of omental flap for prevention of post-operative complications.

Effectiveness not established per policy.

Procedure Components

Integral components not separately reimbursed: Use of fibrin sealant is considered integral to the pancreaticoduodenectomy procedure and not separately reimbursed.

Intervention evidence summaries

Summaries of findings — not explicit coverage rules in these excerpts. Use evidence to inform coverage decisions as below.

Fibrin sealant patch: Trials and systematic reviews found little or no consistent reduction in post-operative pancreatic fistula (POPF), mortality, overall morbidity, re-operation rate, or length of stay after application of fibrin sealants to pancreatic stump or anastomosis; effects are uncertain and evidence quality ranges from very low to moderate.

See randomized trial and Cochrane review summaries.

Pancreatic duct stents: Randomized trials, meta-analyses, and reviews provide limited or low-quality evidence. External stents may lower grade C fistula in some analyses compared with internal stents, but overall effect on clinically relevant POPF is uncertain; stents may modestly reduce hospital LOS. Surgeon preference informs use pending additional RCTs.

See Cochrane and meta-analysis summaries.

Routine nasogastric/gastric decompression (NGTD/RGD): Multiple observational studies, randomized trials, and meta-analyses indicate routine postoperative nasogastric/gastric decompression after PD is not consistently beneficial; selective or no routine decompression is generally safe and may reduce delayed gastric emptying and LOS in some cohorts.

Relaparotomy management

Evidence-based preference when relaparotomy for pancreatic fistula is required

Preference for pancreas-preserving procedure: When relaparotomy is performed for pancreatic fistula after pancreatoduodenectomy, observational cohort and meta-analysis data associate completion pancreatectomy with higher mortality compared with pancreas-preserving procedures (adjusted OR 2.55; meta-analysis OR 1.99).

Based on retrospective multicenter cohort and systematic review/meta-analysis evidence.

PPH prophylaxis

Preventive technique for post-pancreatectomy hemorrhage (PPH)

Falciform ligament wrap: A prophylactic falciform ligament (or falciform/teres) wrap around the hepatic artery and/or gastro-duodenal artery stump may reduce clinically relevant PPH from these vessels; a multi-center RCT showed a non-significant reduction in the modified ITT analysis (2.9% vs 7.1%, p=0.071) and a significant reduction on per-protocol analysis (p=0.017).

Consider during pancreatoduodenectomy to potentially reduce PPH from hepatic or gastro-duodenal artery stump.

Surgical approach considerations

Comparative outcomes by surgical approach

Minimally invasive versus open approaches: When performed in high-volume centers by experienced surgeons, laparoscopic (LPD) and robotic (RPD) pancreaticoduodenectomy have largely comparable short-term perioperative and oncologic outcomes to open PD (OPD). Reported differences include longer operative time for minimally invasive approaches, reduced blood loss for RPD, lower rates of delayed gastric emptying and wound infection for MIS in some analyses, and shorter length of stay for LPD in some studies; learning-curve and center-volume effects are important.

Apply caution during surgeon learning curve; reserve MIS approaches for experienced centers or selected patients.

Evidence summary

Summary of evidence comparing minimally invasive (LPD/robotic) versus open PD and adjunctive vessel wrapping:

RCT and meta-analysis findings: Randomized trials and large meta-analyses report that when performed by experienced surgeons, LPD can have similar mortality and serious morbidity to OPD, with shorter length of stay and reduced blood loss but longer operative time; overall oncologic adequacy appears non-inferior in experienced centers. Evidence synthesis supports comparable short-term outcomes in high-volume settings and suggests vessel-wrapping techniques may reduce extra-luminal hemorrhage but call for larger RCTs.

Supported by multicenter RCTs and large meta-analyses; see vessel wrapping evidence separately.

Regional vessel wrapping

Adjunctive technique to reduce post-operative hemorrhage:

Vessel wrapping reduces bleeding: Systematic review and meta-analysis (2 RCTs and 5 retrospective studies) found a lower incidence of extra-luminal hemorrhage with regional vessel wrapping after pancreaticoduodenectomy (OR 0.51), though authors recommend larger, high-quality RCTs to confirm findings before standard recommendation.

Wrapping materials included omentum, falciform ligament, or ligamentum teres.

The policy explicitly lists ICD-10 code E16.4 (Zollinger‑Ellison syndrome) among diagnosis codes that are not covered for the indications described in this Clinical Policy Bulletin. Pancreaticoduodenectomy for Zollinger‑Ellison syndrome is also identified in the policy text as an experimental and investigational indication and therefore considered not medically necessary for that condition.

A meta‑analysis and the policy statement indicate that routine preoperative biliary drainage (PBD) before pancreaticoduodenectomy is not recommended. PBD was associated with increased post‑operative infectious complications, wound infection, and delayed gastric emptying; the authors concluded PBD probably should not be routinely carried out in patients undergoing PD.

The provided document excerpts do not list additional explicit procedural exclusions beyond those called out elsewhere (for example, Zollinger‑Ellison syndrome and certain adjuncts). Where evidence is uncertain (such as fibrin sealant patches), the text summarizes trial results but does not state a blanket exclusion in these specific chunks.

The policy lists accepted indications for pancreatic head resection—including pancreatic adenocarcinoma, ampullary carcinoma/adenoma, neuroendocrine tumors, cholangiocarcinoma, duodenal neoplasm, combined pancreatic/duodenal injury, and chronic pancreatitis—but these excerpts do not provide explicit exclusions that would prohibit PD when those indications are present.

Minimally invasive pancreaticoduodenectomy (laparoscopic or robotic) is described as technically feasible but also as a complex operation suited only to selected patients. Outcomes are largely comparable to open PD when performed in experienced, high‑volume centers, but the evidence is limited and influenced by learning‑curve effects.

Pancreaticoduodenectomy performed for Zollinger‑Ellison syndrome is identified in the policy as experimental and investigational. Accordingly, PD for ZES is considered not medically necessary under this CPB, and medical therapy (proton‑pump inhibitors) remains the standard initial treatment approach.

Randomized trials and systematic reviews summarized in the policy do not support routine use of fibrin sealant patches or routine gastric decompression to prevent or reduce clinically significant post‑operative pancreatic fistula. The available studies showed little or no consistent benefit in POPF rates, mortality, overall morbidity, re‑operation rate, or length of stay.

Within the provided excerpts there are no explicit statements phrased as general 'not medically necessary' declarations beyond the experimental/investigational items already identified (e.g., PD for Zollinger‑Ellison syndrome, preoperative biliary drainage for prevention of complications, omental flap). Other interventions are discussed with equivocal or limited evidence but are not uniformly labeled 'not medically necessary' in these chunks.

An UpToDate review and the summarized evidence note that robotic‑assisted pancreaticoduodenectomy has not reduced perioperative morbidity or mortality. Laparoscopic PD can yield comparable outcomes in experienced centers but is complex and suitable only for selected patients; high‑quality randomized data remain limited.

Coding and Billing for Pancreaticoduodenectomy

Covered CPT Codes (Whipple-type procedures)CPTCovered

48150	Pancreatectomy, proximal subtotal with total duodenectomy, partial gastrectomy, choledochoenterostomy and gastrojejunostomy (Whipple-type procedure); with pancreatojejunostomy.
48152	Pancreatectomy, proximal subtotal... without pancreatojejunostomy.
48153	Pancreatectomy, proximal subtotal with near-total duodenectomy, choledochoenterostomy and duodenojejunostomy (pylorus-sparing, Whipple-type procedure); with pancreatojejunostomy.
48154	Pancreatectomy, proximal subtotal... without pancreatojejunostomy.

CPT Codes Not Covered for Indications ListedCPTNot Covered

49905

Omental flap, intra-abdominal (List separately in addition to code for primary procedure).

Biliary drainage CPTs (not covered for prevention of complications)CPTNot Covered

47533	Placement of biliary drainage catheter, percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation; external [not covered for prevention of complications].
47534	Placement of biliary drainage catheter, percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation; internal-external [not covered for prevention of complications].
47535	Conversion of external biliary drainage catheter to internal-external biliary drainage catheter, percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, fluoroscopy), and all associated radiological supervision and interpretation [not covered for prevention of complications].
47536	Exchange of biliary drainage catheter (eg, external, internal-external, or conversion of internal-external to external only), percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, fluoroscopy), and all associated radiological supervision and interpretation [not covered for prevention of complications].

Braun enteroenterostomy CPTCPTCovered

44130

Enteroenterostomy, anastomosis of intestine, with or without cutaneous enterostomy (separate procedure) [Braun enteroenterostomy].

ICD-10 Codes Covered if Selection Criteria MetICD-10Covered

C17.0	Malignant neoplasm of duodenum.
C22.1	Intrahepatic bile duct carcinoma.
C24.0	Malignant neoplasm of extrahepatic bile duct.
C24.1	Malignant neoplasm of ampulla of Vater.
C25.0-C25.9	Malignant neoplasm of pancreas.
C7A.00-C7B.8	Neuroendocrine tumors.
D01.49	Carcinoma in situ of other parts of intestine.
D13.6	Benign neoplasm of pancreas.
K86.0	Alcohol-induced chronic pancreatitis.

ICD-10 Codes Not CoveredICD-10Not Covered

E16.4

Increased secretion of gastrin [Zollinger-Ellison syndrome].

HCPCS / OtherHCPCS

Fibrin sealant - no specific code; considered integral to pancreaticoduodenectomy and not separately reimbursed.

Covered CPT CodesCPT

No codes listed

Provider Actions, Prior Authorization, and Documentation

Note

Provider action: None specified

None specified in the provided excerpts.

Billing Rule

Authorization / Billing — no explicit authorization requirements stated

No explicit prior authorization or billing denials are stated in these sections. The CPT codes for pancreaticoduodenectomy (e.g., 48150, 48152, 48153, 48154) and Braun enteroenterostomy (44130) are listed as covered when selection criteria are met; omental flap (49905) and preoperative biliary drainage codes (47533, 47534, 47535) are noted as not covered for prevention of complications. Providers should verify coverage with the payer for individual cases.

Covered CPTs when selection criteria met: 48150, 48152, 48153, 48154
Braun enteroenterostomy covered when criteria met: 44130
Not covered for listed CPB indications: 49905, 47533, 47534, 47535

Note

Provider action: No explicit authorization or billing requirements

No explicit prior authorization or billing requirements are described in the provided excerpts. Treating providers should confirm any payer-specific authorization requirements prior to scheduling.

Documentation Required

Documentation — Risk factor stratification documented in RCTs

Randomized trial(s) and stratified analyses documented risk-factor stratification by gland texture, pancreatic duct size, obesity, and neoadjuvant treatment when assessing interventions (e.g., fibrin sealant patch trial stratified by gland texture, duct size, and neoadjuvant therapy). Providers should document these risk factors in the record when relevant.

Risk factors identified as significant for POPF: obesity, soft gland texture, small duct size
Trials stratified by: gland texture, pancreatic duct size, neoadjuvant therapy

Step Therapy

Step therapy / sequencing

Step therapy / sequencing: No formal step therapy policy is stated. Clinical sequencing noted in background: for Zollinger-Ellison syndrome medical therapy with proton pump inhibitors (PPIs) is standard first-line; surgery (including tumor resection) may be considered when appropriate. For other perioperative strategies, evidence supports selective use (e.g., external vs internal pancreatic duct stents) and further RCTs are needed.

Zollinger-Ellison syndrome: medical therapy (PPIs) is standard before considering surgery
Pancreatic duct stents: evidence on external vs internal stents is limited; more RCTs needed
No formal step therapy or mandated sequencing in these excerpts

Note

Surgical approach preference for relaparotomy

When relaparotomy is required for pancreatic fistula after pancreatoduodenectomy, evidence indicates higher mortality with completion pancreatectomy compared with pancreas-preserving procedures; pancreas-preserving approaches are generally preferred when feasible and should be documented.

Completion pancreatectomy associated with higher mortality versus pancreas-preserving procedures (adjusted OR 2.55)
Document rationale for choice of relaparotomy procedure in the chart

Note

Consider center/surgeon volume for MIPD

Consideration of center and surgeon volume is advised for minimally invasive pancreaticoduodenectomy (MIPD). Current evidence suggests MIPD may have acceptable outcomes when performed at experienced, high-volume centers; registry participation, training, and selective use are recommended.

MIPD outcomes comparable in selected patients when performed at experienced, high-volume centers
Registry participation and prospective evaluation encouraged
Be cautious introducing MIPD during the early learning curve (consider hybrid approaches)

Denial Risk

Denial risk — experimental / investigational indications

Denial triggers: procedures performed for experimental or investigational indications (e.g., pancreaticoduodenectomy for Zollinger-Ellison syndrome) may be considered not medically necessary and subject to denial. Providers should document indications that align with the CPB's listed medically necessary indications.

Zollinger-Ellison syndrome: PD is considered experimental/investigational by Aetna
Ensure documentation supports one of the listed medically necessary indications (e.g., pancreatic adenocarcinoma, ampullary carcinoma, chronic pancreatitis, etc.)

Documentation Required

Required clinical outcome documentation

Required clinical outcome documentation: trials and series commonly report outcomes such as post-operative pancreatic fistula (POPF), mortality, overall morbidity, reoperation, readmission, and length of stay. Providers should include these outcomes in operative and post-operative documentation as appropriate.

Document POPF grade, mortality, morbidity, reoperation/readmission, and hospital length of stay (LOS)

Note

Preoperative biliary drainage — increased complication risk

Preoperative biliary drainage (PBD) is associated with increased infectious complications, wound infection, and delayed gastric emptying in pooled analyses; PBD should not be routinely performed before pancreaticoduodenectomy and use should be justified and documented.

Meta-analysis showed increased risk with PBD: infectious complications (OR 1.52), wound infection (OR 2.09), and DGE (OR 1.37)
Document indication and justification when PBD is performed

Note

Notice about CPB scope and verification

Clinical Policy Bulletin (CPB) scope notice: CPBs assist in administering plan benefits and do not constitute guarantees of coverage. Providers must verify member-specific benefits and eligibility prior to treatment.

CPB is informational and not a contract or coverage guarantee
Participating providers should verify member coverage and authorization requirements

Definitions and Abbreviations

Pancreaticoduodenectomy (Whipple resection) - key details

DefinitionPancreaticoduodenectomy (Whipple resection): surgical removal of the pancreatic head with duodenectomy and reconstruction (proximal pancreatectomy).

Common indicationsAmpullary adenoma/carcinoma; cholangiocarcinoma; chronic pancreatitis; combined pancreatic/duodenal injury; duodenal neoplasm; IPMN with high‑grade dysplasia or invasive cancer; neuroendocrine tumors; pancreatic adenocarcinoma.

Coding rangeTypical CPT codes for Whipple-type procedures: 48150–48154.

PD-specific composite endpoint (CEP)

DefinitionPD-specific composite endpoint (CEP): a proposed composite of 8 clinically significant postoperative complications used as a trial endpoint to improve power and comparability.

Components (8)Intra‑abdominal abscess; sepsis; post‑PD hemorrhage; bile leakage; gastro‑jejunostomy leakage; leakage of the pancreatic anastomosis; delayed gastric emptying; 90‑day operative mortality.

PurposeDesigned to reduce required sample sizes and standardize outcome reporting in randomized trials of PD.

IPMN (intraductal papillary mucinous neoplasm)

DefinitionIntraductal papillary mucinous neoplasm (IPMN): mucin‑producing neoplasm of the pancreatic ductal system; surgery indicated for IPMN with high‑grade dysplasia or invasive cancer.

Surgical optionsResection choice (total pancreatectomy, pancreaticoduodenectomy, distal pancreatectomy, segmental resection) depends on tumor location and extent; pancreaticoduodenectomy is most common for head lesions (~70%).

Prognosis noteSome BRICs from intestinal or gastric IPMN are less aggressive and may have more favorable prognosis compared with conventional lesions.

Surgical variant abbreviations (PPPD / PRPD / CW / PPW)

PPPDPylorus‑preserving pancreaticoduodenectomy — preserves the gastric pylorus during resection.

PRPD (also CW/PPW variants)Pylorus‑resecting pancreaticoduodenectomy (classic Whipple/PPW variants) — resects the pylorus or partial stomach as part of the procedure.

Clinical comparisonRCTs and meta‑analyses show overall similar mortality and morbidity between PPPD and PRPD/CW, with some differences in delayed gastric emptying and perioperative measures in select subgroups.

POPF — postoperative pancreatic fistula

DefinitionPost‑operative pancreatic fistula (POPF): pathological leak from the pancreatic anastomosis or remnant resulting in clinical sequelae; graded (e.g., B/C) in trials and RCTs assessing PD outcomes.

Incidence and gradingIn trials and cohorts, biochemical leakage/POPF and grade B/C fistula rates are reported; example RCT reported biochemical leakage or POPF in 63% vs 56% and grade B/C in 23% vs 14% (patch vs control).

Risk factorsObesity, soft gland texture, and small pancreatic duct size were identified as significant risk factors for POPF in randomized studies.

NGT / NGTD (nasogastric decompression)

DefinitionNasogastric tube decompression (NGT/NGTD): placement and use of a nasogastric (or gastrostomy) tube post‑operatively for gastric decompression after PD.

Clinical findingsRandomized and cohort studies (including IPOD RCT with 111 patients and larger cohorts) found no consistent benefit of routine systematic NGTD versus selective/no NGTD for major complications or LOS.

Practice implicationSelective rather than routine NGT use is generally safe and may reduce delayed gastric emptying and LOS in some series.

Antecolic versus retrocolic reconstruction

Antecolic routeAntecolic reconstruction: gastro‑ or duodenojejunostomy is brought anterior to the transverse colon (antecolic route) when re‑establishing bowel continuity after PD.

Retrocolic routeRetrocolic reconstruction: gastro‑ or duodenojejunostomy is routed posterior to the transverse colon (retrocolic route).

Evidence summaryCochrane review (through July 2021) found low‑to‑moderate certainty evidence suggesting little to no difference between antecolic and retrocolic routes for morbidity, mortality, LOS, or quality of life.

Completion pancreatectomy — definition/notes

DefinitionCompletion pancreatectomy: total removal of the remaining pancreas at relaparotomy (eg, for treatment of severe pancreatic fistula after PD).

Outcome noteRetrospective multicenter data and meta‑analysis associate completion pancreatectomy with higher mortality compared with pancreas‑preserving relaparotomy procedures (adjusted OR 2.55; meta‑analysis OR 1.99).

Recommendation implicationWhen relaparotomy is required for pancreatic fistula after PD, observational evidence favors pancreas‑preserving procedures over completion pancreatectomy when feasible.

RPD / LPD / OPD abbreviations/definitions

RPDRobotic‑assisted pancreatoduodenectomy (RPD): PD performed with robotic assistance; reported to have less blood loss but longer operative times in comparative series.

LPDLaparoscopic pancreatoduodenectomy (LPD): minimally invasive PD via laparoscopy (includes hybrid and total laparoscopic approaches).

OPDOpen pancreatoduodenectomy (OPD): traditional open Whipple resection.

LPD (laparoscopic PD) definition

DefinitionLPD: laparoscopic pancreaticoduodenectomy, encompassing hybrid and total laparoscopic approaches for PD.

Outcomes summaryNetwork and meta‑analyses report similar mortality and serious complications compared with OPD when performed in experienced centers, but LPD often has longer operative time and may have shorter LOS in some studies.

ConsiderationLearning‑curve and center volume are important; many trials emphasize performance in high‑volume centers by experienced surgeons.

OPD (open pancreaticoduodenectomy) definition

DefinitionOPD: open pancreaticoduodenectomy — the traditional, open Whipple resection technique.

Comparative noteCompared with minimally invasive approaches, OPD often has shorter operative time but comparable mortality and oncologic outcomes in pooled analyses.

ContextChoice of approach depends on surgeon experience, center volume, and patient selection; RCT and large meta‑analytic data guide comparisons.

Regional vessels wrapping — omentum/falciform/teres wrap

DefinitionRegional vessels wrapping: surgical wrapping of regional visceral arteries (eg, hepatic artery, gastro‑duodenal artery stump) with omentum or falciform/teres ligament following PD.

MechanismWrap aims to separate vascular stumps from pancreatic leaks and reduce erosion‑related extra‑luminal hemorrhage after PD.

EvidenceSystematic review and meta‑analysis of 2 RCTs and 5 retrospectives (approx. 4,100 patients) found a lower incidence of extra‑luminal hemorrhage with wrapping (OR 0.51, 95% CI: 0.31–0.85).

OpenPayer

Pancreaticoduodenectomy (Whipple Resection)

Coverage Criteria for Pancreaticoduodenectomy (Whipple)

Coding and Billing for Pancreaticoduodenectomy

Provider Actions, Prior Authorization, and Documentation

Background and Rationale

Definitions and Abbreviations